A significant Family Court ruling during 2025 has placed Australia’s medical approach to childhood gender distress under new scrutiny. The case of Re Devin has raised serious questions about expert evidence, the role of advocacy in clinical practice, and whether vulnerable children are being placed on irreversible medical pathways too quickly.
For Women Speak Tasmania, the judgment echo concerns we have heard from parents across the state: that caution, transparency and proper assessment are sometimes being replaced by a one-size-fits-all model of affirmation.
Below we explain what the courts actually found — and why it matters for families.
The Re Devin Decision
In April 2025, Justice Andrew Strum of the Federal Circuit and Family Court of Australia handed down judgment in Re Devin ([2025] FedCFamC1F 211). The case involved a 12-year-old boy whose parents disagreed about medical treatment for gender dysphoria.
The mother supported the commencement of puberty blockers following treatment at the Royal Children’s Hospital (RCH) Melbourne Gender Service. The father opposed medical intervention and sought a therapeutic approach allowing the child to develop without immediate medicalisation.
After reviewing the medical and expert evidence, Justice Strum ruled in favour of the father. He granted him sole parental responsibility for medical decision-making and ordered that puberty blockers or hormones not proceed without both parents’ consent.
The judgment went far beyond a routine parenting dispute. The Court closely examined the clinical assessments underpinning the proposed treatment and found significant shortcomings.
Among the concerns identified:
- the diagnosis was formalised only shortly before court proceedings
- no thorough biopsychosocial assessment had been completed
- screening for conditions such as autism had not been adequately explored
- alternative therapeutic pathways were insufficiently considered
The Court concluded that, particularly in young children, all options should remain open and that early medical intervention carried risks that had not been properly weighed.
Concerns About Expert Evidence
A central feature of the decision was the Court’s criticism of expert testimony presented in support of medical treatment.
Justice Strum found aspects of the evidence to be incomplete and, in places, misleading. He warned that courts must distinguish between independent medical expertise and professional advocacy. Clinical guidelines were described as being presented as authoritative while lacking independent governmental endorsement or long-term outcome evidence.
The Court emphasised a clear principle:
The best interests of the child — not ideology, not institutional preference — must guide decision-making.
The ruling also highlighted that children may lack the maturity to fully understand the lifelong consequences of medical treatment affecting fertility, sexual development and identity formation.
In a subsequent decision (Re Devin No 2 [2025]), the Court permitted the clinicians and hospital involved to be publicly identified, citing the importance of transparency and public confidence.
Why the Case Matters
For more than a decade, Australian legal precedent had generally treated puberty blockers as low-risk and reversible. Earlier cases such as Re Jamie (2013) and Re Kelvin (2017) allowed parents and doctors to authorise treatment without routine court oversight.
However, Re Devin signals a change in judicial approach.
The Court examined newer international evidence — including overseas reviews questioning the strength of the research base — and concluded that medical certainty is far less settled than previously assumed. The judgment stressed that gender dysphoria in children is not necessarily fixed and may evolve over time.
In practical terms, the ruling reinforces several points:
- psychological assessment must be comprehensive
- co-existing conditions must be explored
- alternatives to medicalisation must be considered
- courts will scrutinise expert evidence more closely
A Broader Shift
The case does not stand alone. It arrives alongside increasing international debate about paediatric gender medicine and policy changes in several jurisdictions. Governments, regulators and health authorities are now reviewing evidence on long-term outcomes, consent capacity, and appropriate safeguards.
This is not a rejection of compassion for distressed young people. Children experiencing gender distress deserve care, support and understanding. The question is what form that care should take, and whether irreversible medical interventions should be first-line treatment for minors whose identities are still developing.
What It Means for Families
For parents, the decisions provide reassurance that courts are willing to carefully examine medical evidence rather than simply defer to institutional authority. They also affirm the importance of parental involvement and balanced clinical assessment.
Families are entitled to:
- full information about risks and uncertainties
- consideration of non-medical therapies
- time for development and maturation
- protection from premature irreversible decisions
At its heart, Re Devin is not a culture-war judgment. It is a child-protection judgment. The Court’s task was not to resolve political arguments but to decide what best safeguarded one child.
Its answer was caution.